INTRODUCTION DISCUSSION
Total records identifed through database searching (PubMed and Embase) N = 1269
Records after duplicates removed N = 1085
Articles assessed for full-text eligibility N = 35
Articles included for fnal review N = 8
Articles Excluded N = 27
Records excluded after abstract screening N = 1050
RESULTS
To conduct a systematic review of cost-effectiveness data for omalizumab in the treatment of severe persistent allergic asthma. Asthma is a progressive inflammatory disease which is a major cause of disability, health resource utilization and poor quality of life for those who are affected Asthma is the most common chronic disease among children and young adults, particularly because of its early onset
OBJECTIVE
It is estimated that more than 50% of asthma has an allergic background About 50% of patients with severe asthma have allergic-atopic asthma Current treatment for asthma suggested by Global Initiative for Asthma (GINA) guidelines includes several reliever and controller drugs, specially inhaled corticosteroids which reduce airway inflammation. Other drugs include β2 agonists and anti-leukotrienes Though drugs are effective for most asthma patients, there is a subset of patients in whom none of the drugs can control asthma
IgE antibodies have been viewed as a target for immunological drug development in asthma, and a number of strategies aimed at inhibiting its proinflammatory action have been developed
Omalizumab is the first humanized anti-IgE monoclonal antibody approved for use in bronchial asthma
Since omalizumab is expensive than other anti-asthma drugs, its introduction has increased the treatment cost of the disease But, like all other monoclonal antibodies, omalizumab is extremely expensive Evidence suggest that there is mark variations in cost-effectiveness data for omalizumab in the treatment of severe persistent allergic asthma.
However, there is a substantial uncertainty in the underlying evidence, indicating the need for future research towards reducing such uncertainty.
CONCLUSION
Literature search was conducted in MEDLINE, EMBASE, and Cochrane Library, without any language restrictions, from inception to the end of December 2016
In addition, references of the included studies were screened for additional studies
All studies examining cost-effectiveness of omalizumab in the treatment of severe persistent allergic asthma were included An initial search using the keywords "omalizumab, cost effectiveness, and severe asthma" was followed by a search of related citations Two authors independently selected papers and extracted data; differences adjudicated via consensus discussion Most of the selected studies evaluated add-on omalizumab in patients with allergic asthma that was poorly controlled in spite of high-dose inhaled corticosteroids [ICS, with or without long-acting beta-agonists (LABA)].
MATERIALS AND METHODS
The cost-effectiveness data of omalizumab varied across studies.
Some studies were in favour of omalizumab as a cost-effective or dominant strategy, whereas other studies reported that omalizumab was not cost-effective.
Two of the studies concluded that omalizumab improved health-related quality of life but 6, 7 also substantially increased the cost of treatment.
Another two studies concluded that omalizumab was cost-effective for patients with severe allergic asthma, suggesting that asthma severity and the risk of asthma exacerbations should 8, 9 be considered when determining the cost-effectiveness of omalizumab.
On the contrary, two other studies reported that omalizumab was not cost-effective and noted 10, 11 incremental cost-effectiveness ratios (ICERs) of €38,371 and $821,000.
